Related Experiment Video
Updated: May 24, 2026
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies
Arne Warth1, Roland Penzel, Regine Brandt
1Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 220/221, 69120, Heidelberg, Germany.
Abstract:
Pulmonary adenocarcinoma patients harboring EGFR mutations can benefit from tyrosine kinase inhibitor therapy. Reliable molecular analyses and precise pathological reporting of the EGFR mutational status are factors essential for patient treatment and outcome. More than 70 % of all EGFR mutation analyses are performed on non-small cell lung cancer (NSCLC) biopsies. However, biopsies may not be sufficient for mutation analysis due to low tumor content and admixture with non-neoplastic cells. To define the minimal concentration of tumor cells required for reliable EGFR mutational diagnostics by Sanger sequencing and to develop an algorithm for routine diagnostics on biopsy material, we determined total numbers of tumor and non-tumor cells, calculated the tumor cell concentration and serially diluted DNA from EGFR-mutated NSCLC by adding DNA of non-tumor cells from the same section. A counted tumor cell concentration of 30 %, which refers to a histologically estimated concentration of 40 %, is necessary for reliable detection of all mutations. Based on these data, we developed an algorithm for evidence-based EGFR mutation analysis by Sanger sequencing in biopsy specimens, which was subsequently applied to 461 diagnostic cases. Optimized diagnostic testing results in 80 % reliable EGFR mutation analyses of biopsy specimens, while in 20 % of cases re-biopsies had to be recommended.
Insights
Accurate EGFR mutation analysis in non-small cell lung cancer (NSCLC) biopsies requires a minimum tumor cell concentration. This study defines the threshold for reliable diagnostics and develops an algorithm to improve EGFR mutation testing in NSCLC patients.
Area of Science:
- Oncology
- Molecular Diagnostics
- Genetics
Background:
- EGFR mutations in pulmonary adenocarcinoma predict response to tyrosine kinase inhibitors.
- Accurate EGFR mutational status is crucial for non-small cell lung cancer (NSCLC) treatment and prognosis.
- NSCLC biopsy specimens often have insufficient tumor content for reliable molecular analysis.
Purpose of the Study:
- To determine the minimal tumor cell concentration for reliable EGFR mutation detection in NSCLC biopsies.
- To develop and validate an algorithm for routine EGFR mutation analysis on biopsy material using Sanger sequencing.
Main Methods:
- Serial dilution of DNA from EGFR-mutated NSCLC with non-tumor DNA.
- Determination of tumor and non-tumor cell counts to calculate tumor cell concentration.
- Application of a developed algorithm to 461 diagnostic NSCLC biopsy cases.
Main Results:
- A minimum tumor cell concentration of 30% (counted) or 40% (histologically estimated) is required for reliable EGFR mutation detection.
- The developed algorithm improved the reliability of EGFR mutation analyses in biopsy specimens to 80%.
- 20% of cases still required re-biopsy recommendations due to insufficient tumor content.
Conclusions:
- Establishing a minimal tumor cell concentration threshold is essential for accurate EGFR mutation diagnostics in NSCLC biopsies.
- An evidence-based algorithm significantly enhances the reliability of EGFR mutation testing on limited biopsy material.
- Optimized diagnostic strategies, including potential re-biopsies, are critical for effective targeted therapy selection in NSCLC.
